Heart with magnifying glass revealing a maze in a ventricle, alongside text reading 'ATTR-CM suspect & detect, uncover the clues for diagnosis'

Home > Diagnosis of ATTR-CM

 

Diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

 

The diagnosis of ATTR-CM is often delayed or missed, resulting in an underdiagnosed* cause of heart failure with preserved ejection fraction (HFpEF).1,2

*In two studies, wild-type ATTR deposits were identified in the hearts of 13–17% of older patients with HFpEF.1,2

  • In an ex-US study of 120 HFpEF patients 60 years or older, wild-type ATTR was confirmed in 13% (13.3%; 95% CI: 7.2–19.5) of the patients1
  • In a US study of 441 autopsied patients, 109 of whom had HFpEF, cardiac wild-type ATTR deposits were found in 17% of the patients2
Black call to action button containing the text: 'recognising the signs and symptoms of ATTR-CM' alongside an image of a red heart with yellow arteries
Learn more here >
Black call to action button containing the text: 'Consider the Clinical Clues to Identify ATTR-CM and the Need for Further Testing' alongside an image of a white magnifying glass
Learn more here >
Black call to action button containing the text: 'Formal Diagnosis of ATTR-CM' alongside an image of a yellow heart with a red beat line
Learn more here >

 

NEXT SECTION: Recognising signs and symptoms of ATTR-CM >

 

References

  1. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015; 36(38): 2585–2594. 
  2. Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014; 2(2): 113–122.

PP-VYN-GBR-0181. March 2020

Click here for Vyndaqel ▼ (tafamidis) prescribing information